<DOC>
	<DOC>NCT01610479</DOC>
	<brief_summary>This is a phase 1 study of TAS-114 in combination with S-1 in patients with advanced solid tumors.</brief_summary>
	<brief_title>A Study of TAS-114 in Combination With S-1 in Patients With Advanced Solid Tumors</brief_title>
	<detailed_description>This is a phase 1, open-label, non-randomized, dose-escalating safety, tolerability, and pharmacokinetic study of TAS-114 in combination with S-1 in patients with advanced solid tumors.</detailed_description>
	<criteria>Life expectancy of at least 3 months Histological or cytological documentation of advanced solid tumors ECOG Performance Status of â‰¤ 1 (ECOG: Eastern Cooperative Oncology Group) Adequate bone marrow, liver and renal function Women of childbearing potential and men must agree to use adequate contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>